Dyskinesia News and Research

RSS
New infusion therapy may help avoid debilitating symptoms in Parkinson's disease patients

New infusion therapy may help avoid debilitating symptoms in Parkinson's disease patients

UAB researchers uncover vital mechanism for L-DOPA-induced-dyskinesia

UAB researchers uncover vital mechanism for L-DOPA-induced-dyskinesia

Defects in cerebrospinal fluid flow may contribute to scoliosis during adolescence

Defects in cerebrospinal fluid flow may contribute to scoliosis during adolescence

Neurocrine Biosciences reports net loss of $29.3 million for fourth quarter 2015

Neurocrine Biosciences reports net loss of $29.3 million for fourth quarter 2015

Opicapone simplifies levodopa-related motor fluctuation treatment

Opicapone simplifies levodopa-related motor fluctuation treatment

SynAgile announces positive results from Phase 2a trial of continuous intraoral LD/CD therapy

SynAgile announces positive results from Phase 2a trial of continuous intraoral LD/CD therapy

Neurocrine Biosciences announces positive data from NBI-98854 Phase III trial in tardive dyskinesia

Neurocrine Biosciences announces positive data from NBI-98854 Phase III trial in tardive dyskinesia

Invitae announces dramatic expansion of genetic testing menu

Invitae announces dramatic expansion of genetic testing menu

Study reveals why long-term use of L-DOPA leads to dyskinesia

Study reveals why long-term use of L-DOPA leads to dyskinesia

University of Maryland Medicine offers MRI-guided focused ultrasound treatment to Parkinson's patients

University of Maryland Medicine offers MRI-guided focused ultrasound treatment to Parkinson's patients

Researchers perform first focused ultrasound treatments in the U.S. for dyskinesia

Researchers perform first focused ultrasound treatments in the U.S. for dyskinesia

Putaminal serotonergic innervation flags levodopa-induced dyskinesia risk

Putaminal serotonergic innervation flags levodopa-induced dyskinesia risk

Neurocrine completes enrollment in Phase III clinical trial of NBI-98854 in tardive dyskinesia patients

Neurocrine completes enrollment in Phase III clinical trial of NBI-98854 in tardive dyskinesia patients

Pitt researchers figure out how to quantify beating action of cilia

Pitt researchers figure out how to quantify beating action of cilia

Severe dyskinesias rare in community Parkinson’s cohort

Severe dyskinesias rare in community Parkinson’s cohort

Pharma Two B reports positive results from P2B001 Phase IIb study for treatment of early stage PD

Pharma Two B reports positive results from P2B001 Phase IIb study for treatment of early stage PD

Clinical studies confirm safety, efficacy of opicapone in Parkinson’s disease patients

Clinical studies confirm safety, efficacy of opicapone in Parkinson’s disease patients

NTCELL Phase I/IIa clinical study meets primary endpoint in patients with Parkinson’s disease

NTCELL Phase I/IIa clinical study meets primary endpoint in patients with Parkinson’s disease

FVCG portfolio companies selected to present research at Bio International 2015

FVCG portfolio companies selected to present research at Bio International 2015

Neurocrine reports net loss of $1.2 million for first quarter 2015

Neurocrine reports net loss of $1.2 million for first quarter 2015